In cases of relapsed or refractory (R/R) AML with FLT3 mutations, the use of TKI compared to high-dose chemotherapy alone, such as gilteritinib (ADMIRAL study) (14) and quizartinib (QuANTUM-R study) (15), has also shown significant improvements in overall survival. The gene discussed is FLT3; the disease is acute myeloid leukemia.